| GTx Has to Reevaluate Options Following Prostate Cancer Drug Failure EP Vantage submits:GTx’s (GTXI) main shot at redemption for its lead pipeline candidate, toremifene (acapodene), failed to deliver with the release Tuesday night of phase III data that showed no significant reduction in the risk of developing prostate cancer in patients with a premalignant lesion.Having already failed to convince the FDA of the drug’s effectiveness and safety in preventing bone fractures in men undergoing prostate cancer treatment (FDA words not sticks and stones hurt GTx’s bone drug, November 2, 2009), the results from this three-year, 1,600 patient study could have provided a major boost to toremifene’s prospects. Instead, GTx’s shares slumped 31% to a record low of $2.09 in early trade Wednesday, valuing the company at $76m, a major fall from grace having been worth $450m just six months ago.Complete Story » seekingalpha.com |
Device Helps Heart Patients; Concerns Cited A new medical device from Medtronic helps patients with a common faulty heartbeat but, in some cases, has caused injuries to a nearby nerve. online.wsj.com |
New Hepatitis Therapy Could Be Vertex's Windfall The Burrill Report submits: By Michael FitzhughVertex Pharmaceutical (VRTX) says a new trial shows that its late-stage hepatitis C therapy, telaprevir, can help some people tackle the virus in half the time the current treatment takes. A quicker cure, one slashing typical treatment times to 24 weeks from 48 weeks, could help millions of infected people stick to their treatment regimens and represent a windfall for Vertex. Complete Story » seekingalpha.com |
Garry D. Johnson Joins BioClinica as Senior Vice President and Chief Technology Officer [Business Wire] - NEWTOWN, Pa.----BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, today announced the appointment of Garry D. Johnson as Senior Vice President and Chief Technology Officer , a newly created position. us.rd.yahoo.com |
BSD Medical: Christmas Could Come Early for Investors Investment U submits: By Alexander MoschinaIt’s the future of cancer treatment. Plus, at just three feet tall, and weighing a mere 25 pounds, it’s also one of the smallest devices of its kind. In addition, it uses a fraction of the power used by other machines, but generates much higher temperatures. That means the doctors that use it can spend less money and kill more cancerous cells.Complete Story » seekingalpha.com |